3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Rare Diseases
1
Paraproteinemias
1
Neuromyelitis Optica
1
Neurologic Manifestations
1
Nervous System Diseases
1
Neoplasms, Plasma Cell
1
Myelitis, Transverse
1
Myasthenia Gravis
1
Multiple Sclerosis
1
Multiple Myeloma
1
Mental Disorders
1
Kidney Diseases
1
Hematologic Diseases
1
Encephalomyelitis, Acute Disseminated
1
Diffuse Cerebral Sclerosis of Schilder
1
Autoimmune Diseases
1
Acute Kidney Injury
1
Interventions
Gemcitabine
13
pembrolizumab
9
Specimen Handling
9
enfortumab vedotin
8
Cisplatin
8
Magnetic Resonance Spectroscopy
7
avelumab
5
Carboplatin
5
vinflunine
4
Nivolumab
4
atezolizumab
3
Immunoglobulin G
3
Disulfides
3
Biopsy
3
eribulin
2
cabozantinib
2
Standard of Care
2
Ramucirumab
2
Radiotherapy
2
Platinum
2
Nephroureterectomy
2
Ipilimumab
2
Doxorubicin
2
Docetaxel
2
CTLA-4 Antigen
2
Bortezomib
2
1,2-diaminocyclohexaneplatinum II citrate
2
vandetanib
1
tremelimumab
1
tocilizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Ureteral Neoplasms
×
Plasma Exchange
×
Clear all
NCT07087860
2026-05-08
RECIPE-B1
Mayo Clinic
Phase 2
Recruiting
70 enrolled